ALNY Alnylam Pharmaceuticals Stock Outlook 2026: The RNAi Platform Faces Its Biggest Test in ATTR-CM
Alnylam Pharmaceuticals (ALNY) stock outlook 2026. A qualitative look at the RNAi/siRNA platform, the four-product commercial franchise, the Amvuttra opportunity in ATTR cardiomyopathy versus Pfizer's tafamidis and BridgeBio's acoramidis, the Novartis/Roche/Regeneron royalty model, nucresiran's late-stage trials, and the path to sustained profitability.
ALNY Alnylam RNAi